Radiation Oncology (Feb 2023)

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors—retrospective study

  • Hajime Higaki,
  • Kentaro Nishioka,
  • Manami Otsuka,
  • Noboru Nishikawa,
  • Motoyasu Shido,
  • Hideki Minatogawa,
  • Yukiko Nishikawa,
  • Rikiya Takashina,
  • Takayuki Hashimoto,
  • Norio Katoh,
  • Hiroshi Taguchi,
  • Rumiko Kinoshita,
  • Koichi Yasuda,
  • Takashi Mori,
  • Yusuke Uchinami,
  • Fuki Koizumi,
  • Yoshihiro Fujita,
  • Shuhei Takahashi,
  • Takahiro Hattori,
  • Noriaki Nishiyama,
  • Hidefumi Aoyama

DOI
https://doi.org/10.1186/s13014-023-02218-3
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed. Methods We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for BM initially at the Hokkaido Cancer Center. We evaluated the effect on the prognosis of Lung-molGPA items, the expression of PD-L1 (classified as high, low, and no expression), and the treatment history. The main outcome was the survival measured from the day of the diagnosis of BM, and log-rank tests were performed to evaluate the results. Results The median overall survival (OS) times for adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, 2.5‒3.0, and 3.5‒4.0) were 5.5, 14.8, 28.3, and 39.0 months (p < 0.0001), respectively. The median survival times for non-adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, and 2.5‒3.0) were 3.2, 11.0, and 16.0 months (p = 0.0011), respectively. In adenocarcinoma patients with gene mutations, osimertinib significantly improved the outcome (median OS: 34.2 and 17.6 months with and without osimertinib, respectively (p = 0.0164)). There was no significant difference in the OS between patients who were initially treated with tyrosine-kinase inhibitor for BM and those who initially received radiotherapy (p = 0.5337). In patients tested for PD-L1 expression, the median survival times after the diagnosis of BM were 5.6, 22.5, and 9.3 months for the high-, low- and no-expression groups (p = 0.2198), respectively. Also, in patients with high PD-L1 expressions, those with ICI had survival (median OS, 8.6 months) than those without (median OS, 3.6 months). Conclusions We confirmed that Lung-molGPA successfully classified Japanese NSCLC patients with BM by the prognosis. Osimertinib prolonged survival of EGFR-positive NSCLC patients with BM, and ICI was effective in patients with high PD-L1 expressions.

Keywords